Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities.

摘要: Immunosuppressive cells have been reported to play an important role in tumor progression mainly because of their capability promote immune-escape, angiogenesis and metastasis. Among them, myeloid derived suppressor (MDSCs) recently identified as immature cells, induced by tumor-associated inflammation, able impair both innate adaptive immunity. While murine MDSCs are usually the expression CD11b Gr-1, human represent a more heterogeneous population characterized CD33 CD11b, low or no HLA-DR variable CD14 CD15. In particular, last two may alternatively identify monocyte-like granulocyte-like MDSC subsets with different immunosuppressive properties. Recently, substantial increase has found peripheral blood bone marrow (BM) multiple myeloma (MM) patients disease and/or drug resistance. Preclinical models recapitulating complexity MM-related BM microenvironment (BMM) major tools for study interactions between MM BMM (including MDSCs) development new agents targeting MM-associated immune suppressive cells. This review will focus on current strategies generation investigation function vitro vivo, taking into account relevant relationship occurring within MM-BMM. We then provide trends MDSC-associated research suggest potential application treatment MM.